Journal for ImmunoTherapy of Cancer – Page 14

Atezolizumab and bevacizumab, with or without radiotherapy, versus docetaxel in patients with metastatic non-small cell lung cancer previously treated with a checkpoint inhibitor and chemotherapy: results from the randomized, phase Ib/II MORPHEUS-Lung study

5 de August de 2025 by

Background
Options remain limited for patients requiring later lines of therapy for metastatic non-small cell lung cancer (mNSCLC) due to poor prognosis and potential toxicities. Therefore, trials of novel combinations of existing therapeutic candidat…

HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer

4 de August de 2025 by

Background
Ovarian cancer represents the most lethal gynecological cancer with poor response to checkpoint inhibitors. Human endogenous retroviruses (HERVs) are aberrantly expressed by tumor cells and may represent a source of shared T-cell epitopes f…

Lipid nanoparticle-delivered IFN{alpha}2 activates Cxcl9 to increase T cell tumor recruitment to suppress lung metastasis

1 de August de 2025 by

Background
Emerging clinical and mouse tumor data indicate that tumor cells induce immune suppression in an anatomical site-specific manner. In lung metastases, tumor cell programmed death-ligand 1 (PD-L1) engages myeloid cell programmed cell death pr…

Lipid nanoparticle-delivered IFN{alpha}2 activates Cxcl9 to increase T cell tumor recruitment to suppress lung metastasis

1 de August de 2025 by

Lipid nanoparticle-delivered IFN{alpha}2 activates Cxcl9 to increase T cell tumor recruitment to suppress lung metastasis

1 de August de 2025 by

Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine

31 de July de 2025 by

Background
A chemoimmunotherapy regimen consisting of a novel Wilms’ tumor 1 (WT1) peptide-pulsed dendritic cell (WT1-DC) vaccine and multiagent chemotherapy was observed to modulate the tumor microenvironment (TME) to an immunostimulatory state…

Universal Fab-Fc masked cytokine prodrug platform: {alpha}PD-L1/IL-15 prodrug activates CD44+ CD8+ T cells in tumor-draining lymph nodes to enhance antitumor immunity

31 de July de 2025 by Song, L., Qi, G., Shi, W., Zeng, Q., Qin, Y., Wang, Z., Li, W., Song, Z., Zhang, A., Lu, H.

Background
Immunocytokines targeting immune checkpoints have shown great potential in overcoming resistance to immune checkpoint blockade (ICB), making them a major focus of development in recent years. However, severe dose-limiting toxicity hindered …

Is immunotherapy safe and effective in patients with VEXAS syndrome?

31 de July de 2025 by

The use of immune checkpoint inhibitors in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is unknown. Concerns are particularly about their safety, due to their potential capacity to exacerbate inflammatory symptoms. Further…

Letter to the editor: caution in translational leap – are the data sufficient to generalize low-dose PDT to chest malignancies?

31 de July de 2025 by Zhang, Y., Yu, X.

Integrated system for screening tumor-specific TCRs, epitopes, and HLA subtypes using single-cell sequencing data

31 de July de 2025 by Wang, X., Song, X., Li, Y., Ding, Y., Yin, C., Ren, T., Zhang, W.

Background
T-cell receptor (TCR)-T immunotherapy has emerged as a promising strategy for cancer treatment. However, identifying TCRs that can be used to generate TCR-T cells remains challenging due to tumor heterogeneity, the scarcity of tumor-specifi…